138 related articles for article (PubMed ID: 31945380)
1. Chemoradiotherapy-induced Cytodifferentiation in Bladder/Prostate Rhabdomyosarcoma With Genetic Downregulation of Myogenin and MyoD1 Gene Expression: A Case Study and Review of the Literature.
Agard H; Clark C; Massanyi E; Steele M; McMahon D
Urology; 2020 Mar; 137():173-177. PubMed ID: 31945380
[TBL] [Abstract][Full Text] [Related]
2. Myogenin and desmin immunohistochemistry in the assessment of post-chemotherapy genitourinary embryonal rhabdomyosarcoma: prognostic and management implications.
Godbole P; Outram A; Wilcox DT; Duffy PG; Sebire NJ
J Urol; 2006 Oct; 176(4 Pt 2):1751-4. PubMed ID: 16945640
[TBL] [Abstract][Full Text] [Related]
3. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
[TBL] [Abstract][Full Text] [Related]
5. Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.
Michelagnoli MP; Burchill SA; Cullinane C; Selby PJ; Lewis IJ
Med Pediatr Oncol; 2003 Jan; 40(1):1-8. PubMed ID: 12426678
[TBL] [Abstract][Full Text] [Related]
6. Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas.
Sebire NJ; Malone M
J Clin Pathol; 2003 Jun; 56(6):412-6. PubMed ID: 12783965
[TBL] [Abstract][Full Text] [Related]
7. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis-1 and Rhabdomyosarcoma: An Unusual Recurrence.
Halstead NV; Cost NG; Hecht SL; Walker JP
Urology; 2020 Mar; 137():168-172. PubMed ID: 31794814
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of new monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of rhabdomyosarcoma.
Cui S; Hano H; Harada T; Takai S; Masui F; Ushigome S
Pathol Int; 1999 Jan; 49(1):62-8. PubMed ID: 10227726
[TBL] [Abstract][Full Text] [Related]
10. A new human pleomorphic rhabdomyosarcoma cell-line, HS-RMS-1, exhibiting MyoD1 and myogenin.
Sonobe H; Takeuchi T; Taguchi T; Shimizu K; Furihata M; Ohtsuki Y
Int J Oncol; 2000 Jul; 17(1):119-25. PubMed ID: 10853028
[TBL] [Abstract][Full Text] [Related]
11. Embryonal rhabdomyosarcoma of the adult soft palate.
Bhutoria S; Oneil C
Indian J Pathol Microbiol; 2011; 54(1):136-7. PubMed ID: 21393897
[TBL] [Abstract][Full Text] [Related]
12. Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma.
Paner GP; McKenney JK; Epstein JI; Amin MB
Am J Surg Pathol; 2008 Jul; 32(7):1022-8. PubMed ID: 18469707
[TBL] [Abstract][Full Text] [Related]
13. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood.
Wang NP; Marx J; McNutt MA; Rutledge JC; Gown AM
Am J Pathol; 1995 Dec; 147(6):1799-810. PubMed ID: 7495304
[TBL] [Abstract][Full Text] [Related]
14. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of New Monoclonal Anti-MyoD1 (MX049) for the Diagnosis of Rhabdomyosarcoma: Comparison with 5.8A, EP212, Anti-Desmin, Anti-Myogenin, and Fluorescence
He Y; Chen X; Yu X
Ann Clin Lab Sci; 2020 May; 50(3):412-416. PubMed ID: 32581037
[TBL] [Abstract][Full Text] [Related]
16. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience.
Morotti RA; Nicol KK; Parham DM; Teot LA; Moore J; Hayes J; Meyer W; Qualman SJ;
Am J Surg Pathol; 2006 Aug; 30(8):962-8. PubMed ID: 16861966
[TBL] [Abstract][Full Text] [Related]
18. Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma: Results from IRS IV.
Arndt CA; Hammond S; Rodeberg D; Qualman S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):563-7. PubMed ID: 17006261
[TBL] [Abstract][Full Text] [Related]
19. Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma.
Fine SW; Lisanti MP; Argani P; Li M
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):231-6. PubMed ID: 16082247
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience.
Rekhi B; Gupta C; Chinnaswamy G; Qureshi S; Vora T; Khanna N; Laskar S
Ann Diagn Pathol; 2018 Oct; 36():50-60. PubMed ID: 30098515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
